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Balancing gastrointestinal benefitrisk in individuals
who are prescribed NSAIDs for arthritis
Musculoskeletal problems and conditions are widespread
and their impact is pervasive. They are the most common
cause of severe long-term pain and physical disability,
affecting hundreds of millions of people around the
world [1]. Those predominantly affecting joints are collec-
tively called arthritis. Arthritis is quite common: one in four
Europeans has some form of arthritis or rheumatism and
one in five is under long-term treatment for it [2]. As our
population ages, these numbers are unlikely to go down.
The burden of rheumatic diseases may not be heavy in
terms of mortality but the effect on daily life is significant.
In fact, it has been reported that musculoskeletal condi-
tions have the greatest impact on quality of life compared
with other diseases [3, 4]. One UK report found that when
their arthritis is bad, 69% of people have difficulty in
carrying out daily tasks and 54% even struggle to get
out of bed [5].
Our primary aim in treating someone with any form of
arthritis is to stop the progression of the disease and to
help the patient to live as active and pain free a life as
possible. Medical professionals have a range of treat-
ments to offer people with arthritis or other forms of rheu-
matism. In the treatment of RA and SpA, major progress
has been made in the last decade and NSAIDs are now
used less in these patients. However, the number of
patients with OA is increasing and NSAIDs are now used
extensively by these (often elderly) patients, who quite
frequently also have one or more comorbidities. As the
European League Against Rheumatism (EULAR) guide-
lines on the treatment of OA clearly state, a combination
of non-pharmacological and pharmacological treatment
modalities is needed for optimal management [6]. Our
first port of call is lifestyle changes with exercise and
weight loss where appropriate, in addition to other
non-pharmacological options including physiotherapy,
education and coping programmes. The effect sizes
(ESs) of these interventions may be limited (ES often in
the range of 0.20) and partly due to placebo effects [7].
Where these need to be supplemented, there is a range of
pharmacological treatments from local glucocorticoid
injections to topical creams as well as oral pain relief
[6, 8]. Paracetamol (acetaminophen) is the first oral anal-
gesic to try. When this is not effective, we have the option
of NSAIDs, with opioids as an alternative in those patients
who are unresponsive to NSAIDs or intolerant of them [6].
The ESs of these NSAIDs are moderate (ES50.50) and
they are preferred by many patients. It is the decision
about when to use NSAIDs—with the benefit of efficacy
and the risks for some patients—that is the focus of this
supplement.
Samuel Johnson, the 18th-century English essayist,
said judgement is forced upon us by experience. In fact,
he implies that without experience we prefer not to make
judgements. As physicians, we have to make judgements
every day. Our judgements are often a question of asses-
sing benefit vs risk. In some situations, it is clear what
treatment or advice should be given. In others, a careful
analysis of the benefits and risks by both physician and
patient is needed to decide on the best course of action.
As physicians, our judgements are based not only on our
own experience by what we find out through our own
practice, but also on other people’s experience and on
what we read in journals and discuss with our colleagues.
As research and experience constantly expand, then
although the objective of our judgement remains the
same—achieving the best outcome for the patient—our
knowledge base offers us an increasing amount of infor-
mation to help us make this judgement.
This is certainly true of NSAIDs—both non-selective and
Cox-2-selective inhibitors. Choosing whether to treat a
patient with an anti-inflammatory drug and deciding
which one will suit a patient best, is a decision that
requires us to consider several aspects of a patient’s
health. From the early use of salicin in the 5th-century
BC, it was noted that the anti-inflammatory aspirin had
gastrointestinal (GI) side effects. The same phenomenon
was reported in the 1980s when ibuprofen began to be
sold over the counter. Then, in the 1990s, the issue of
cardiovascular (CV) risk appeared and now we have a
picture of both non-selective NSAIDs and Cox-2-selective
inhibitors having CV risk that varies from agent to agent
and which is often dose related.
In the three papers that comprise this supplement, we
look at the benefitrisk judgements that we make about
non-selective NSAIDs and Cox-2s when we are treating a
patient with arthritis. How do we weigh up all the different
factors in order to give a patient as much benefit as pos-
sible while minimizing risk?
Professor Lanas examines new data on the increase in
numbers of lower GI events and illustrates how serious
lower GI complications can be. He considers how this
fits into the context of assessing GI risk in the entire GI
tract and looks at a new end-point for establishing
whether our arthritis patients are experiencing lower GI
events. This may enable assessment of GI health without
sophisticated techniques such as balloon endoscopy.
There is a dearth of studies with lower GI events as their
primary end-point to aid with this difficult issue and it is
hoped that the outcome of the celecoxib or diclofenac
and omeprazole for gastrointestinal safety in high
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study will add valuable evidence to enable improved
patient outcomes.
In the second paper in the supplement, I review the
evidence for the degree of CV and GI risk across the
range of anti-inflammatory treatments and consider how
we decide which treatment will give the most benefit and
minimize risk in this population of patients who often pre-
sent with increased risk of a cardiac event, GI risk factors
or both. The cases where a Cox-2 may be more suitable
than a non-selective NSAID with or without gastroprotec-
tion are considered.
Dr Richard Ward, a Canadian family physician, asks
how we manage the kind of cases often seen in primary
care, where older individuals present with a range of
comorbidities and complex polypharmacy. He focuses
particularly on the evidence for the efficacy of NSAIDs
when given with frequently used concomitant medication,
such as aspirin, ACE-inhibitor or selective serotonin
re-uptake inhibitors (SSRIs).
I hope that considering all these aspects of using both
non-selective NSAIDs and Cox-2s in individuals with
arthritis will give you a clear idea of the evidence we cur-
rently have based on our study and personal experiences.
This experience should facilitate well-informed judge-
ments about what treatment we prescribe for the patients
in our care.
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